ElsaLys takes rights to Transgene's anti-CD115 mAb for immuno-oncology
ElsaLys SAS licensed all development and marketing rights to Transgene SA’s immune-oncology candidate TG3003, which it will rename ELB041.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com